Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nucleolar organizer regions in mesothelial proliferations.
Ramael M, Van den Bossche J, Buysse C, Van Marck E. Ramael M, et al. Among authors: van den bossche j, van marck e. J Pathol. 1992 Aug;167(4):435. doi: 10.1002/path.1711670414. J Pathol. 1992. PMID: 1403363 No abstract available.
The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
Deben C, Wouters A, Op de Beeck K, van Den Bossche J, Jacobs J, Zwaenepoel K, Peeters M, Van Meerbeeck J, Lardon F, Rolfo C, Deschoolmeester V, Pauwels P. Deben C, et al. Among authors: van den bossche j, van meerbeeck j. Oncotarget. 2015 Sep 8;6(26):22666-79. doi: 10.18632/oncotarget.4433. Oncotarget. 2015. PMID: 26125230 Free PMC article.
In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J, Deben C, De Pauw I, Lambrechts H, Hermans C, Deschoolmeester V, Jacobs J, Specenier P, Pauwels P, Vermorken JB, Peeters M, Lardon F, Wouters A. Van den Bossche J, et al. Mol Oncol. 2019 May;13(5):1196-1213. doi: 10.1002/1878-0261.12477. Epub 2019 Apr 5. Mol Oncol. 2019. PMID: 30859681 Free PMC article.
Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.
Van den Bossche J, De Laere M, Deschepper K, Germonpré P, Valcke Y, Lamont J, Stein B, Van Camp K, Germonpré C, Nijs G, Roelant E, Anguille S, Lion E, Berneman Z. Van den Bossche J, et al. PLoS One. 2024 Jul 15;19(7):e0307204. doi: 10.1371/journal.pone.0307204. eCollection 2024. PLoS One. 2024. PMID: 39008481 Free PMC article.
146 results